UA76483C2 - Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof - Google Patents

Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof Download PDF

Info

Publication number: UA76483C2
Authority: UA; Ukraine
Prior art keywords: crystalline form; crystalline; pyrrole; carboxamide; diethylamino
Prior art date: 2001-08-15

Application number

UA2004021084A

Other languages

English (en)

Ukrainian (uk)

Inventor

Thomas J Fleck

Stephen P Prescott

Mark T Maloney

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-15

Filing date

2002-08-13

Publication date

2006-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA76483(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-13 Application filed by Upjohn Co filed Critical Upjohn Co

2006-08-15 Publication of UA76483C2 publication Critical patent/UA76483C2/uk

Links

238000000034 method Methods 0.000 title abstract description 53
239000000203 mixture Substances 0.000 title abstract description 47
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title abstract description 10
150000004701 malic acid derivatives Chemical class 0.000 title abstract description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title description 18
239000013078 crystal Substances 0.000 abstract description 78
150000003839 salts Chemical class 0.000 description 48
239000001630 malic acid Substances 0.000 description 46
239000008194 pharmaceutical composition Substances 0.000 description 34
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 32
235000011090 malic acid Nutrition 0.000 description 32
238000002425 crystallisation Methods 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
230000008025 crystallization Effects 0.000 description 30
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 29
239000000843 powder Substances 0.000 description 26
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
239000002904 solvent Substances 0.000 description 25
-1 2-(diethylamino)ethyl Chemical group 0.000 description 24
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
150000003857 carboxamides Chemical class 0.000 description 20
239000000463 material Substances 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 18
238000002441 X-ray diffraction Methods 0.000 description 17
239000000725 suspension Substances 0.000 description 16
239000002253 acid Substances 0.000 description 15
238000001816 cooling Methods 0.000 description 14
238000002844 melting Methods 0.000 description 13
230000008018 melting Effects 0.000 description 13
239000007787 solid Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000000546 pharmaceutical excipient Substances 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
XMEDONBRMQPJIX-UHFFFAOYSA-N 2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CC1=CNC(C)=C1C(N)=O XMEDONBRMQPJIX-UHFFFAOYSA-N 0.000 description 8
239000011549 crystallization solution Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
239000002775 capsule Substances 0.000 description 7
238000004090 dissolution Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000001179 sorption measurement Methods 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000012458 free base Substances 0.000 description 6
238000000634 powder X-ray diffraction Methods 0.000 description 6
CPECNDIGIFHFKM-UHFFFAOYSA-N 1,2-dimethylpyrrole-3-carboxamide Chemical compound CC1=C(C(N)=O)C=CN1C CPECNDIGIFHFKM-UHFFFAOYSA-N 0.000 description 5
239000000969 carrier Substances 0.000 description 5
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000008298 dragée Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
102000009465 Growth Factor Receptors Human genes 0.000 description 3
108010009202 Growth Factor Receptors Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000000892 gravimetry Methods 0.000 description 3
238000000227 grinding Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000000155 melt Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002411 thermogravimetry Methods 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
238000007707 calorimetry Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000002178 crystalline material Substances 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000010959 steel Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000007704 transition Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
244000056139 Brassica cretica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
XMWZRPFGTUYNJT-UHFFFAOYSA-N C[CH]N(CC)CC Chemical group C[CH]N(CC)CC XMWZRPFGTUYNJT-UHFFFAOYSA-N 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000032027 Essential Thrombocythemia Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
229950005567 benzodepa Drugs 0.000 description 1
VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004320 controlled atmosphere Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000013265 extended release Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
239000003667 hormone antagonist Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000010985 leather Substances 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000005065 mining Methods 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229940045681 other alkylating agent in atc Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
229950001100 piposulfan Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960004694 prednimustine Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
239000004576 sand Substances 0.000 description 1
238000000646 scanning calorimetry Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
230000002381 testicular Effects 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
201000002131 testis sarcoma Diseases 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
229950001353 tretamine Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
229950006929 uredepa Drugs 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
239000002966 varnish Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Obesity (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)

UA2004021084A 2001-08-15 2002-08-13 Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof UA76483C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31235301P	2001-08-15	2001-08-15
PCT/US2002/025649 WO2003016305A1 (fr)	2001-08-15	2002-08-13	Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes

Publications (1)

Publication Number	Publication Date
UA76483C2 true UA76483C2 (en)	2006-08-15

Family

ID=23211067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2004021084A UA76483C2 (en)	2001-08-15	2002-08-13	Crystalline form of malic acid salt of n-\|2-(diethylamino)ethyl\|-5-\|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof

Country Status (42)

Country	Link
US (2)	US20030069298A1 (fr)
EP (3)	EP3168218B1 (fr)
JP (1)	JP4159988B2 (fr)
KR (1)	KR100639281B1 (fr)
CN (2)	CN100364991C (fr)
AP (1)	AP1660A (fr)
AR (1)	AR036261A1 (fr)
AU (1)	AU2002324684B2 (fr)
BG (1)	BG108553A (fr)
BR (1)	BR0211612A (fr)
CA (1)	CA2455050C (fr)
CO (1)	CO5550431A2 (fr)
CU (1)	CU23713B7 (fr)
CY (1)	CY1121552T1 (fr)
CZ (1)	CZ2004196A3 (fr)
DK (2)	DK1419151T3 (fr)
EA (1)	EA006445B9 (fr)
EC (1)	ECSP044975A (fr)
ES (3)	ES2623094T3 (fr)
GE (1)	GEP20063777B (fr)
HR (1)	HRP20040112B1 (fr)
HU (1)	HU229206B1 (fr)
IL (1)	IL160097A0 (fr)
IS (1)	IS7147A (fr)
MA (1)	MA27058A1 (fr)
ME (1)	ME00414B (fr)
MX (1)	MXPA04001452A (fr)
MY (1)	MY139383A (fr)
NO (1)	NO326508B1 (fr)
NZ (1)	NZ531232A (fr)
OA (1)	OA12650A (fr)
PL (1)	PL216524B1 (fr)
PT (2)	PT3168218T (fr)
RS (1)	RS53251B (fr)
SI (2)	SI1419151T1 (fr)
SK (1)	SK902004A3 (fr)
TN (1)	TNSN04028A1 (fr)
TR (1)	TR201900509T4 (fr)
TW (1)	TWI269796B (fr)
UA (1)	UA76483C2 (fr)
WO (1)	WO2003016305A1 (fr)
ZA (1)	ZA200400706B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100364991C (zh)	2001-08-15	2008-01-30	法玛西雅厄普约翰美国公司	2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
TW200418836A (en) *	2002-09-10	2004-10-01	Pharmacia Italia Spa	Formulations comprising an indolinone compound
NZ546001A (en) *	2003-10-02	2009-09-25	Pharmacia & Upjohn Co Llc	Salts and polymorphs of a pyrrole-substituted indolinone compound
US20060009510A1 (en) *	2004-07-09	2006-01-12	Pharmacia & Upjohn Company Llc	Method of synthesizing indolinone compounds
EP2233482A1 (fr) *	2004-07-22	2010-09-29	Eli Lilly And Company	Hydrate cristallin variable de sel (S)-6-(4-(2-((3-(9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarboxamide hemisuccinate
AU2006245421A1 (en) *	2005-05-12	2006-11-16	Pfizer Inc.	Anticancer combination therapy using sunitinib malate
KR101050906B1 (ko) *	2005-09-19	2011-07-20	화이자 프로덕츠 인크.	피롤 치환된 2-인돌리논의 고체 염 형태
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
US20100256392A1 (en) *	2007-11-21	2010-10-07	Teva Pharmaceutical Industries Ltd.	Polymorphs of sunitinib base and processes for preparation thereof
EP2220071A2 (fr)	2007-11-21	2010-08-25	Teva Pharmaceutical Industries Ltd.	Hémi-l-malate de sunitinib, polymorphes et leur préparation, polymorphes de malate de sunitinib racémique, compositions contenant une base de sunitinib et de l'acide malique et leur préparation
CA2709083A1 (fr) *	2007-12-12	2009-06-18	Medichem S.A.	Formes polymorphes d'une 2-indolinone substituee par 3-pyrrole
EP2113248A1 (fr)	2008-04-29	2009-11-04	Ratiopharm GmbH	Composition pharmaceutique comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (fr)	2008-02-13	2009-08-19	Ratiopharm GmbH	Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2252607A2 (fr) *	2008-02-21	2010-11-24	Generics [UK] Limited	Nouveaux polymorphes et procédés de préparation
EP2098521A1 (fr) *	2008-03-06	2009-09-09	Ratiopharm GmbH	Formules cristallines de N-[2-(diéthylamino)éthyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidène)méthyl]-2,4-diméthyl-1H-pyrrole-3-carboxamide
WO2009124037A1 (fr) *	2008-03-31	2009-10-08	Teva Pharmaceutical Industries Ltd.	Procédés de préparation de sunitinib et de sels de ce dernier
WO2009128083A1 (fr) *	2008-04-16	2009-10-22	Natco Pharma Limited	Nouvelles formes polymorphes du sunitinib base
RU2468022C2 (ru) *	2008-05-23	2012-11-27	Шанхай Инститьют Оф Фармасьютикал Индастри	Производные дигидроиндолона
ES2392762T3 (es) *	2008-06-13	2012-12-13	Medichem, S.A.	Procedimiento para preparar una sal de malato de 2-indolinona sustituida con 3-pirrol
EP2138167A1 (fr)	2008-06-24	2009-12-30	ratiopharm GmbH	Compositions pharmaceutiques comportant du N-[2-(diethylamino)ethyl]-5-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (fr) *	2008-06-26	2009-12-30	Medichem, S.A.	Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole
JP2011527330A (ja) *	2008-07-10	2011-10-27	ジェネリクス・（ユーケー）・リミテッド	スニチニブリンゴ酸塩の結晶形の調製方法
CA2731605A1 (fr) *	2008-07-24	2010-01-28	Teva Pharmaceutical Industries Ltd.	Sunitinib et ses sels et leurs polymorphes
EP2342195B1 (fr) *	2008-07-24	2014-09-10	Medichem, S.A.	Formes cristallines d un sel de malate de 2-indolinone à substitution 3-pyrrole
CN102197034A (zh) *	2008-08-25	2011-09-21	基因里克斯(英国)有限公司	舒尼替尼的新型多晶型物及其制备方法
JP2012500837A (ja) *	2008-08-25	2012-01-12	ジェネリクス・（ユーケー）・リミテッド	新規な結晶型およびその調製方法
AR073807A1 (es) *	2008-10-10	2010-12-01	Medichem Sa	Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
EP2181991A1 (fr)	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Nouveaux sels de sunitinib
EP2186809A1 (fr) *	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	Nouvelle forme cristalline du malate de sunitinib
US8329740B2 (en)	2009-01-02	2012-12-11	Hetero Research Foundation	Polymorphs of sunitinib malate
NZ779754A (en)	2009-01-16	2023-04-28	Exelixis Inc	Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP2255792A1 (fr)	2009-05-20	2010-12-01	Ratiopharm GmbH	Composition pharmaceutique pour n-[2-(diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1h-pyrrole-3-carboxamide
WO2011004200A1 (fr)	2009-07-10	2011-01-13	Generics [Uk] Limited	Nouveaux dérivés de pyrrole
EP2477978A1 (fr)	2009-09-16	2012-07-25	Ranbaxy Laboratories Limited	Sels de sunitinib
EP2499133A2 (fr)	2009-11-12	2012-09-19	Ranbaxy Laboratories Limited	Procédé de préparation de la forme cristalline i du sel d'acide l-malique de sunitinib
US8916716B2 (en)	2009-11-19	2014-12-23	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
US20130210885A1 (en)	2010-01-29	2013-08-15	Ranbaxy Laboratories Limited	Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (fr)	2010-02-09	2011-08-18	Sicor Inc.	Polymorphes de sels de sunitinib
WO2011104555A2 (fr)	2010-02-25	2011-09-01	Generics [Uk] Limited	Nouveau procédé
AU2011222470A1 (en)	2010-03-04	2012-09-27	Ranbaxy Laboratories Limited	Process for the direct preparation of malic acid salt of sunitinib
CA2793359A1 (fr)	2010-03-18	2011-09-22	Ranbaxy Laboratories Limited	Procede pour la preparation du sel de l'acide maleique du sunitinib
WO2011128699A2 (fr)	2010-04-16	2011-10-20	Generics [Uk] Limited	Procédés inédits
WO2012042421A1 (fr)	2010-09-29	2012-04-05	Pfizer Inc.	Procédé de traitement de la croissance cellulaire anormale
DK2699598T3 (en)	2011-04-19	2019-04-23	Pfizer	COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
US9206163B2 (en)	2012-03-23	2015-12-08	Laurus Labs Private Ltd.	Process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl)	2012-04-27	2013-10-28	Instytut Farmaceutyczny	Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
RU2737765C2 (ru)	2012-05-04	2020-12-02	Пфайзер Инк.	Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CA2838587A1 (fr)	2013-10-18	2015-04-18	Hari Babu Matta	Forme cristalline pure ii de sel d'acide l-malique de sunitinib et procede pour sa preparation
CA2838585A1 (fr)	2013-10-18	2015-04-18	Hari Babu Matta	Sel de sunitinib d'acide ascorbique
WO2015063647A1 (fr)	2013-11-01	2015-05-07	Pfizer Inc.	Vecteurs d'expression d'antigènes associés à la prostate
CN104693187A (zh) *	2013-12-10	2015-06-10	安杰世纪生物科技（北京）有限公司	一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) *	2013-12-25	2019-05-28	江苏豪森药业集团有限公司	苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) *	2014-10-01	2015-11-10	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) *	2014-12-05	2016-06-29	广州白云山医药集团股份有限公司白云山制药总厂	一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (fr)	2018-03-15	2019-09-18	MH10 Spolka z ograniczona odpowiedzialnoscia	Composition pharmaceutique de sunitinib ou de son sel dans sa forme polymorphe i
SG11202111339WA (en) *	2019-04-18	2021-11-29	Meter Health Inc	Methods and compositions for treating respiratory arrhythmias
EP3958845A1 (fr)	2019-04-25	2022-03-02	Synthon B.V.	Composition pharmaceutique comprenant du sunitinib amorphe
JP7633786B2 (ja) *	2020-09-18	2025-02-20	日本化薬株式会社	スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko)	2022-08-19	2024-02-27	주식회사 스카이테라퓨틱스	무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL170330B1 (pl)	1990-10-15	1996-11-29	Pfizer	Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL
IL100091A (en)	1990-12-12	1998-08-16	Zeneca Ltd	Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
DE69318212T2 (de)	1992-06-05	1998-11-19	Merck Sharp & Dohme	Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie
KR100296810B1 (ko)	1993-03-12	2001-10-24	로렌스 티. 마이젠헬더	결정성세프티오퍼유리산
US6329364B1 (en) *	1994-08-31	2001-12-11	Eli Lilly And Company	Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) *	1995-02-07	1998-07-02	Mack Chem Pharm	Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) *	1995-05-30	1997-01-28	Motorola, Inc.	Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) *	1995-07-06	1997-10-07	Moore; James R.	Instructional toothbrush
US20020045746A1 (en) *	1995-12-11	2002-04-18	Barton Kathleen P.	Eplerenone crystalline form
US20020038021A1 (en) *	1995-12-11	2002-03-28	Barton Kathleen P.	Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) *	1996-07-29	2000-05-23	Pfizer Inc.	Zwitterionic forms of trovafloxacin
CZ297679B6 (cs)	1996-08-14	2007-03-07	G. D. Searle & Co.	Krystalická forma B 4-[5-methyl-3-fenylizoxazol-4-yl]benzensulfonamidu
WO1998029344A1 (fr) *	1996-12-25	1998-07-09	Nippon Kayaku Kabushiki Kaisha	Poudre de cisplatine fine et son procede de production
US5777185A (en) *	1997-09-09	1998-07-07	Laroche Industries Inc.	Production of organic fluorine compounds
US6133305A (en) *	1997-09-26	2000-10-17	Sugen, Inc.	3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) *	1998-01-26	2000-01-11	The Boeing Company	Galley vacuum waste disposal system
CA2566652C (fr) *	1998-06-19	2008-10-21	Teijin Limited	Modifications permettant de synthetiser des polymorphes de l'acide 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylique et methodes de preparation connexes
BR9916327A (pt) *	1998-12-17	2001-09-18	Hoffmann La Roche	Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
US6239141B1 (en)	1999-06-04	2001-05-29	Pfizer Inc.	Trovafloxacin oral suspensions
WO2001037820A2 (fr) *	1999-11-24	2001-05-31	Sugen, Inc.	Formulations pour agents pharmaceutiques ionisables comme acides libres ou bases libres
JP3663382B2 (ja)	2000-02-15	2005-06-22	スージェン・インコーポレーテッド	ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
US6316672B1 (en) *	2001-01-31	2001-11-13	Grayson Walker Stowell	Form a of fluoxetine hydrochloride
CN100364991C (zh)	2001-08-15	2008-01-30	法玛西雅厄普约翰美国公司	2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
EP2252607A2 (fr)	2008-02-21	2010-11-24	Generics [UK] Limited	Nouveaux polymorphes et procédés de préparation
WO2009156837A2 (fr)	2008-06-26	2009-12-30	Medichem, S.A.	Forme amorphe d'un sel de malate de 2-indolinone à substitution 3-pyrrole

2002
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/fr not_active Expired - Lifetime
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko not_active Expired - Lifetime
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/fr not_active Expired - Lifetime
- 2002-08-13 CA CA002455050A patent/CA2455050C/fr not_active Expired - Lifetime
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/fr not_active Expired - Lifetime
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/fr not_active Ceased
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Ceased
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown

Also Published As

Publication number	Publication date
TWI269796B (en)	2007-01-01
EP1419151B1 (fr)	2014-02-26
US20030069298A1 (en)	2003-04-10
EP2332934B1 (fr)	2017-03-01
CA2455050C (fr)	2007-02-20
IS7147A (is)	2004-02-10
US20070191458A1 (en)	2007-08-16
EP2332934A1 (fr)	2011-06-15
CY1121552T1 (el)	2020-05-29
CZ2004196A3 (cs)	2005-01-12
CN1789264A (zh)	2006-06-21
HU229206B1 (en)	2013-09-30
TNSN04028A1 (fr)	2006-06-01
CN100439360C (zh)	2008-12-03
HK1066542A1 (en)	2005-03-24
HRP20040112A2 (en)	2004-06-30
MXPA04001452A (es)	2004-05-20
KR20040030074A (ko)	2004-04-08
CO5550431A2 (es)	2005-08-31
ZA200400706B (en)	2005-05-25
BR0211612A (pt)	2004-08-24
KR100639281B1 (ko)	2006-10-31
NZ531232A (en)	2004-11-26
DK1419151T3 (da)	2014-03-31
NO326508B1 (no)	2008-12-15
ES2453164T3 (es)	2014-04-04
TR201900509T4 (tr)	2019-02-21
EA006445B9 (ru)	2017-02-28
AR036261A1 (es)	2004-08-25
BG108553A (bg)	2005-04-30
EP3168218B1 (fr)	2018-11-14
HRP20040112B1 (en)	2012-03-31
CU20040029A7 (es)	2008-03-14
DK3168218T3 (en)	2019-01-14
AU2002324684B2 (en)	2006-10-05
PL368317A1 (en)	2005-03-21
GEP20063777B (en)	2006-03-27
CN1543462A (zh)	2004-11-03
ME00414B (me)	2011-10-10
MY139383A (en)	2009-09-30
ES2623094T3 (es)	2017-07-10
AP2004002976A0 (en)	2004-03-31
IL160097A0 (en)	2004-06-20
EP1419151A1 (fr)	2004-05-19
JP4159988B2 (ja)	2008-10-01
SI1419151T1 (sl)	2014-04-30
MA27058A1 (fr)	2004-12-20
RS53251B (sr)	2014-08-29
HK1088008A1 (zh)	2006-10-27
EP3168218A1 (fr)	2017-05-17
WO2003016305A1 (fr)	2003-02-27
NO20041054L (no)	2004-03-12
CA2455050A1 (fr)	2003-02-27
PT1419151E (pt)	2014-03-27
CN100364991C (zh)	2008-01-30
PT3168218T (pt)	2019-01-11
US7435832B2 (en)	2008-10-14
EA006445B1 (ru)	2005-12-29
CU23713B7 (es)	2011-10-05
ECSP044975A (es)	2004-03-23
OA12650A (en)	2006-06-19
RS10304A (sr)	2007-02-05
EA200400183A1 (ru)	2004-08-26
ES2705063T3 (es)	2019-03-21
PL216524B1 (pl)	2014-04-30
SK902004A3 (sk)	2005-03-04
JP2005503386A (ja)	2005-02-03
AP1660A (en)	2006-09-09
HUP0700036A2 (en)	2008-10-28
SI3168218T1 (sl)	2019-05-31

Publication	Publication Date	Title
UA76483C2 (en)	2006-08-15	Crystalline form of malic acid salt of n-\|2-(diethylamino)ethyl\|-5-\|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof
AU2002324684A1 (en)	2003-05-29	Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
CN121202731A (zh)	2025-12-26	(r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的晶体、其组合物及用途
US10954235B2 (en)	2021-03-23	Crystalline forms of valbenazine salts
CN101501029A (zh)	2009-08-05	N-(2-乙酰基-4,6-二甲基苯基)-3-{[(3,4-二甲基-5-异噁唑基)-氨基]磺酰}-2-噻吩酰胺的多晶型物
HK1066542B (en)	2009-07-10	Crystals including a malic acid salt of n-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxo-3h-indole-3-ylidene) methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
HK1088008B (en)	2008-08-08	2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
HK40009279A (en)	2020-06-26	Solvate form of (r)-2-amino-3-phenylpropyl carbamate